These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 39093942)
21. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Raha P; Thomas S; Thurn KT; Park J; Munster PN Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915 [TBL] [Abstract][Full Text] [Related]
22. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered? Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592 [TBL] [Abstract][Full Text] [Related]
23. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067 [TBL] [Abstract][Full Text] [Related]
24. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model. Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446 [TBL] [Abstract][Full Text] [Related]
25. Effects of novel HDAC inhibitors on urothelial carcinoma cells. Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501 [TBL] [Abstract][Full Text] [Related]
26. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894 [TBL] [Abstract][Full Text] [Related]
30. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma. Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906 [TBL] [Abstract][Full Text] [Related]
31. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057 [TBL] [Abstract][Full Text] [Related]
32. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403 [TBL] [Abstract][Full Text] [Related]
33. Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma. Zhang Q; Yang L; Liu YH; Wilkinson JE; Krainer AR Sci Transl Med; 2023 Apr; 15(691):eadd8280. PubMed ID: 37043556 [TBL] [Abstract][Full Text] [Related]
34. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Schulte JD; Buerki RA; Lapointe S; Molinaro AM; Zhang Y; Villanueva-Meyer JE; Perry A; Phillips JJ; Tihan T; Bollen AW; Pekmezci M; Butowski N; Oberheim Bush NA; Taylor JW; Chang SM; Theodosopoulos P; Aghi MK; Hervey-Jumper SL; Berger MS; Solomon DA; Clarke JL Neurooncol Adv; 2020; 2(1):vdaa142. PubMed ID: 33354667 [TBL] [Abstract][Full Text] [Related]
35. Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones. Sarthy JF; Meers MP; Janssens DH; Henikoff JG; Feldman H; Paddison PJ; Lockwood CM; Vitanza NA; Olson JM; Ahmad K; Henikoff S Elife; 2020 Sep; 9():. PubMed ID: 32902381 [TBL] [Abstract][Full Text] [Related]
36. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation. Hutt DM; Roth DM; Marchal C; Bouchecareilh M Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814 [TBL] [Abstract][Full Text] [Related]
37. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Kurundkar D; Srivastava RK; Chaudhary SC; Ballestas ME; Kopelovich L; Elmets CA; Athar M Toxicol Appl Pharmacol; 2013 Jan; 266(2):233-44. PubMed ID: 23147569 [TBL] [Abstract][Full Text] [Related]
38. Epidermal stem cells are defined by global histone modifications that are altered by Myc-induced differentiation. Frye M; Fisher AG; Watt FM PLoS One; 2007 Aug; 2(8):e763. PubMed ID: 17712411 [TBL] [Abstract][Full Text] [Related]
39. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806 [TBL] [Abstract][Full Text] [Related]
40. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]